These findings provide further insights into possible mechanisms behind how Rab5a hyperactivation‐mediated NGF signal loss affects AD pathology and reveal the molecular mechanism of EA treatment, which increases basal forebrain hippocampal circuit plasticity and improves cognitive performance in patients with Alzheimer's disease. The gene discussed is RAB5A; the disease is early-onset autosomal dominant Alzheimer disease.